Teoxane releases new antiageing serum

Kate Byng-Hall on December 13, 2024

Aesthetic manufacturer Teoxane has unveiled the new antiageing retinol-alternative [R] Advanced Serum.

The company shares that the product contains bakuchiol and peptide actives to mimic the effects of retinol – collagen synthesis and protection, skin renewal, skin firmness and minimised wrinkles and fine lines.

A study of 70 participants found that after 28 days of use, 94% felt their skin seemed firmer, 92% said their skin felt younger and they saw a 10% reduction in number of wrinkles.

Dr Pamela Benito, aesthetic practitioner and medical director of Clinic Shiro, said, “I highly recommend the Teoxane [R] Advanced Serum. As a great alternative to retinol, it contains bakuchiol which stimulates collagen production with a more tolerable formula. It is as effective at reducing fine lines and wrinkles and improving skin tone, but perfect for sensitive skin!”

Advertorial: Meet the Trainer: Understanding the Power of HA Filler

Kate Byng-Hall on December 12, 2024

Four Teoxane UK trainers share their advice on utilising hyaluronic acid fillers.Hyaluronic acid (HA) fillers have revolutionised the field of medical aesthetics. With their unparalleled versatility, HA fillers provide aesthetic practitioners with the tools to deliver bespoke, natural-looking results tailored …

To access this post, you must purchase Aesthetics Journal Membership – Annual Elite Membership, Aesthetics Journal Membership – Annual Enhanced Membership or Aesthetics Journal Membership – Basic Membership.

Teoxane hosts educational XPAND conference

Mia Sawyer on November 14, 2024

On October 21 global aesthetic manufacturer Teoxane delivered the XPAND conference in London.

250 delegates attended the event, with the agenda covering topics surrounding aesthetics, led by key professionals within the specialty. Leading AI Strategist, Katie King, covered the topic of AI within aesthetics, discussing AI tools for personalising patient interactions and boosting satisfaction. Social media consultant, Andrew Davis, sharing master digital platforms to broaden marketing horizons and personalise your brand online.

The afternoon of XPAND comprised clinical content such as cadaver reviews, anatomy and Anatomy, Technique, Product (ATP) overviews, plus three live demonstrations showcasing ATP treatment fundamentals in each area. Dr Lee Walker explored the ageing process with tailored treatment plans, while Dr Tahera Bhojani Lynch, Dr Raul Cetto and Dr Raj Thethi carried out a review of upper body anatomy with evidence-based treatment tips.

Additionally, Jimmy Faivre, innovation manager for Teoxane, flew in from Geneva to discuss new innovations for the future of the company. Faivre discussed the future use of Mepivacaine to replace lidocaine as an anaesthetic, a new syringe design launch and the evolution of crosslinking technologies.

Alongside the conference, Teoxane has introduced a programme with XPAND to launch in 2025. The strategy is aiming to support clinics across all touch points of their businesses, ranging from marketing and branding, to evidence-based clinical training and consultation planning.

Sandra Fishlock, managing director of Teoxane, commented, “XPAND 2024 represents not just an event, but a community of forward-thinking practitioners and innovators. Our HCP partners’ passion and dedication are what drive the future of aesthetics, and we are honoured to be on this journey with each and every one of the exceptional practitioners that make up our specialty.”

Teoxane unveils two-step product authentication approach

Kate Byng-Hall on August 1, 2024

Aesthetic manufacturer Teoxane has enhanced its product authentication process with holographic seals and distribution QR codes.

Teoxane explains that from July 2024 onwards, every product box from the company will include a holographic seal of authenticity on the box. Each box will also have a unique LOT number so its progress through the manufacturing and distribution process can be tracked to ensure authenticity. A QR code on the box will allow practitioners to double check the authenticity of this process, ensuring it has been safely delivered to the UK.

Hannah Nolan, national sales manager at Teoxane UK, said, “As one of the world’s leading dermal filler brands, we integrate expertise and meticulous attention to detail into every step of the manufacturing, packaging and distribution process, so that our partners and their patients can be assured that every box of Teoxane dermal filler is safe and of the highest quality that they have come to expect. The introduction of our new two-step authentication process will help to fortify and protect our HCPs and patients, ensuring the legitimacy of the Teoxane products that they purchase in the UK, and ensuring that they are not only high quality, but get them the results that they desire and deserve.”

Teoxane appoints two new product specialists

Kate Byng-Hall on May 24, 2024

Global aesthetic manufacturer Teoxane has announced the appointment of two new product specialists to its UK team.

Chris Boyle and Stuart Young have joined the company as product specialist for Scotland and product specialist East respectively.

Teoxane says both additions to the team will be pivotal in driving the company’s growth in their respective regions, as well as providing new and existing Teoxane customers and healthcare professionals with support.

Hannah Nolan, national sales manager at Teoxane UK Ltd, said, “At the forefront of innovation since 2003, Teoxane is dedicated to evolving the industry and enhancing safety through clinical excellence and medical education. We’re delighted to welcome Boyle and Young to the Teoxane UK team as our new product specialists for Scotland and East and look forward to the experience and skills that they bring to their respective roles and our UK business.”

Teoxane unveils new regional expert

Ellie Holden on April 9, 2024

Global aesthetic manufacturer Teoxane has welcomed aesthetic practitioner Dr Bonny Armstrong to its faculty as regional expert in Ireland.

According to the company, Dr Armstrong will support Teoxane with their global education initiatives as well as support Teoxane’s product specialist Grainne Hutton in delivering regional based training throughout the north and south of Ireland.

Dr Armstrong said, “I’m delighted to join Teoxane’s esteemed faculty as regional expert in Ireland. Teoxane are true leaders in the field of dermal filler education, and I’m looking forward to delivering clinically relevant, tailored and connected training to fellow healthcare professionals in the coming months so that we can work together to enhance patient care and outcomes.”

Teoxane receives MDR certification for product portfolio

Ellie Holden on December 18, 2023

Global aesthetic manufacturer Teoxane has been granted Medical Device Regulation (MDR) certification for two of its injectable products.

The company has become the first to manufacture sterile, injectable, hyaluronic acid-based products specifically to treat wrinkles and to have its entire product portfolio (Teosyal PureSense and Teosyal RHA) recognised for the safety and quality of its therapeutic and aesthetic properties, notes the company.

Introduced in May 2017 and in effect since May 2021, the MDR imposed stricter requirements for performance and safety assessments, technical documentation, post-marketing monitoring and regarding responsibilities of medical device manufacturers, distributors and importers.

The company has demonstrated the quality and safety of Teosyal PureSense and Teosyal RHA products through 14 clinical studies conducted in Europe and the US, showcasing the clinical performance of the products, Teoxane says. Valérie Taupin, CEO and founder of Teoxane, said, “Receiving this approval is a source of great pride for us and a testament to our commitment to safety and clinical excellence, which are central to our product design. At Teoxane, our ambition goes beyond mere compliance with standards. We aspire to be pioneers, anticipating regulatory implementation and innovating with solutions that will raise standards in our industry, for the benefit of patients.”